Find policies, billing codes, payers, states, and providers
CPT 95913: Nerve Conduction Studies, 13 or More
CPT code 95913 denotes an extensive nerve conduction testing service comprising 13 or more studies to assess motor and sensory peripheral nerve conduction. This code is used in diagnostic electrodiagnostic evaluations for conditions such as neuropathies, radiculopathies, and focal nerve lesions. Nationally, accurate use of this code matters for clinical documentation, specialty service lines in neurology and clinical neurophysiology, and correct claims processing for higher-volume electrodiagnostic encounters.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for 95913, comparisons to related electrodiagnostic codes for smaller study volumes, and practical claims elements that affect billing classification. The summary highlights common clinical indications and typical sites of service where these studies are performed.
The publication provides benchmarks and coding relationships — including how 95913 relates to lower-volume nerve conduction codes — plus payer coverage considerations and coding pitfalls to avoid. It also outlines the clinical scenarios that commonly generate the need for 13 or more studies, helping coders and administrators place 95913 appropriately within electrodiagnostic service lines.
Customize your policy alerts
Sign up for cpt 95913 policy alerts
Get alerted when payer policies referencing 95913 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 95913 describes a diagnostic procedure for performing 13 or more nerve conduction studies. The test evaluates the electrical conduction function of motor and sensory peripheral nerves to identify neuropathic processes and guide diagnosis.
Service Type: Nerve conduction studies (extensive)
Typical Site of Service: Electrodiagnostic laboratory or outpatient neurology clinic, where specialized equipment and trained personnel conduct nerve conduction testing.
National Reimbursement Benchmarks
Medicare’s national mean of $207.20 sits noticeably below BUCA’s average commercial mean of $309.10, indicating a sizable gap of $101.90 between public and the BUCA commercial benchmark for CPT 95913. This gap highlights that commercial payers on average reimburse substantially more than Medicare for this code, with BUCA representing a higher average market position relative to the federal program.
Measuring dispersion by the interquartile range (P75−P25) highlights variation across payers: Blue Cross Blue Shield shows a tight spread of $139.20 (P75 $379.70 − P25 $240.50), while UnitedHealth Group and Cigna have wider spreads of $210.00 (UnitedHealth Group: $407.10 − $186.10) and $244.30 (Cigna: $390.90 − $164.60), respectively. Aetna’s spread is $161.10 and BUCA’s is $166.40; Medicare’s IQR is $167.50. Thus Cigna exhibits the widest dispersion and Blue Cross Blue Shield the tightest.